Canagliflozin is a novel, orally selective inhibitor of sodium-dependent glucose co-transporter-2 (SGLT2) for the treatment of patients with type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.